"New Therapies for Multiple Myeloma Provide Optimistic Outlook"
With the approval of four drugs, 2015 was a monumental year for multiple myeloma, and Sundar Jagannath, MD, director of the Multiple Myeloma Program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, is optimistic about the years to come. In an interview with Cure, Dr. Jagannath discusses which emerging agents he is most excited about, sequencing challenges in multiple myeloma and the role for personalized medicine in the disease. Learn more.
Press Release
Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
Aug 22, 2019 View All Press Releases